BackgroundCheck.run
Search For

Karen L Menge, 61884 Vale View Dr, Vista, CA 92081

Known as:
Karen Lynn Menge Karen L Weinstock Karen L Menghe
Related to:
Deborah Smith Edwards 68

Karen Menge Phones & Addresses

884 Vale View Dr, Vista, CA 92081    410-6086870   

San Marcos, CA   

847 University Ave, Baltimore, MD 21210    410-4671254   

4096 Lark St, San Diego, CA 92103   

2228 Felspar St #D, San Diego, CA 92109   

4676 Noyes St, San Diego, CA 92109   

4676 Noyes St #F, San Diego, CA 92109   

Encinitas, CA   

Orange, CA   

847 W University Pkwy, Baltimore, MD 21210    410-4671254   

Social networks

Karen L Menge

Linkedin

Work

Company: Chromacode, inc. Oct 2015 Position: Vice president research and development

Education

Degree: Doctorates, Doctor of Philosophy School / High School: The Johns Hopkins University Specialities: Biochemistry

Skills

Fda • Technology Transfer • Biotechnology • Medical Devices • Life Sciences • Clinical Trials • Validation • Infectious Diseases • Gmp • Commercialization • Pharmaceutical Industry • Sop • Molecular Biology • Biochemistry • R&D • Assay Development • Regulatory Affairs • Quality Assurance • Laboratory • Product Development • Quality System • Lifesciences • Molecular Diagnostics • Microbiology • Iso 13485 • Personalized Medicine • Research and Development • Quality Management • Hardware Diagnostics • Pcr • Glp • Capa • Cell Biology • U.s. Food and Drug Administration • Immunoassays • Virology • Cell • Good Laboratory Practice • Corrective and Preventive Action • Polymerase Chain Reaction

Industries

Biotechnology
Get Report
Control this profile

Mentions for Karen L Menge

Karen Menge resumes & CV records

Resumes

Karen Menge Photo 22

Vice President Research And Development

Location:
884 Vale View Dr, Vista, CA 92081
Industry:
Biotechnology
Work:
Chromacode, Inc.
Vice President Research and Development Animalgesic Labs Nov 2013 - 2015
Senior Director Operations and Manager Regulatory Affairs Global Scientific Solutions For Health (Gsshealth) 2012 - 2015
Director of Programs Karen L Menge Consulting 2009 - 2015
Principal Consultant Novartis 2010 - 2012
Associate Director Development, Infectious Diseases Falls Road Running Store 2008 - 2010
Manager, Operations Innurvation 2007 - 2008
Vice President Regulatory, Clinical and Scientific Affairs Nanogen 2002 - 2007
Director, Product Development and Clinical Trials Manager Nanogen 2000 - 2002
Staff Scientist and Program Leader Microgenomics 1997 - 2000
Senior Scientist University of San Diego 1995 - 1997
Instructor, Chemistry and Biochemistry Agouron Pharmaceuticals 1993 - 1996
Postdoctoral Fellow and Scientist
Education:
The Johns Hopkins University
Doctorates, Doctor of Philosophy, Biochemistry University of California, Davis
Bachelors, Bachelor of Science, Biochemistry
Skills:
Fda, Technology Transfer, Biotechnology, Medical Devices, Life Sciences, Clinical Trials, Validation, Infectious Diseases, Gmp, Commercialization, Pharmaceutical Industry, Sop, Molecular Biology, Biochemistry, R&D, Assay Development, Regulatory Affairs, Quality Assurance, Laboratory, Product Development, Quality System, Lifesciences, Molecular Diagnostics, Microbiology, Iso 13485, Personalized Medicine, Research and Development, Quality Management, Hardware Diagnostics, Pcr, Glp, Capa, Cell Biology, U.s. Food and Drug Administration, Immunoassays, Virology, Cell, Good Laboratory Practice, Corrective and Preventive Action, Polymerase Chain Reaction

Publications & IP owners

Us Patents

Methods And Apparatus For Screening And Detecting Multiple Genetic Mutations

US Patent:
2004014, Jul 29, 2004
Filed:
Jul 24, 2003
Appl. No.:
10/627950
Inventors:
Ray Radtkey - San Diego CA, US
Lance Held - San Marcos CA, US
Robert Wallace - Escondido CA, US
Karen Menge - San Diego CA, US
David Canter - San Diego CA, US
Assignee:
Nanogen, Inc.
International Classification:
C12Q001/68
US Classification:
435/006000
Abstract:
An assay system and methods are described where patient samples containing genomic DNA are analyzed for the presence of known genetic polymorphisms using a universal reporter strategy. In a preferred embodiment, the amplified DNA is localized at test sites in an array of sites on a microchip followed by a series of hybridization reactions that screen for the presence of a single mutation from among a number of mutations, and allow the identification of specific mutations. In addition to universal reporters, the assay may use blockers and discriminators for screening and identification of known polymorphisms.

Methods And Apparatus For Screening And Detecting Multiple Genetic Mutations

US Patent:
2010016, Jul 1, 2010
Filed:
Oct 7, 2009
Appl. No.:
12/574875
Inventors:
Ray R. Radtkey - San Diego CA, US
Lance C. Held - San Marcos CA, US
Robert B. Wallace - Escondido CA, US
Karen Menge - San Diego CA, US
David Canter - San Diego CA, US
International Classification:
C40B 60/12
US Classification:
506 39
Abstract:
An assay system and methods are described where patient samples containing genomic DNA are analyzed for the presence of known genetic polymorphisms using a universal reporter strategy. In a preferred embodiment, the amplified DNA is localized at test sites in an array of sites on a microchip followed by a series of hybridization reactions that screen for the presence of a single mutation from among a number of mutations, and allow the identification of specific mutations. In addition to universal reporters, the assay may use blockers and discriminators for screening and identification of known polymorphisms.

Competitive Probes For Engineering Signal Generation

US Patent:
2020008, Mar 19, 2020
Filed:
Nov 21, 2019
Appl. No.:
16/690427
Inventors:
- Carlsbad CA, US
Aditya RAJAGOPAL - Orange CA, US
Karen L. MENGE - San Marcos CA, US
Gregory GOSCH - San Diego CA, US
International Classification:
C12Q 1/6818
G01N 33/58
G01N 21/64
C12Q 1/6888
C12Q 1/6827
C12Q 1/6804
C12Q 1/686
C12Q 1/6816
Abstract:
A method of identifying a first target nucleic acid comprising, providing a sample comprising the first target nucleic acid, providing a first set of paired oligonucleotides with complementarity to the first target nucleic acid, the first set of paired oligonucleotides comprising a first ratio of (a) first competitive oligonucleotides to (b) first signal oligonucleotides comprising a signal tag, wherein the competitive oligonucleotides compete with the signal oligonucleotides for binding to the first target nucleic acid, amplifying the first target nucleic acid with the polymerase chain reaction, thereby degrading the first signal oligonucleotide and permitting generation of a first signal, generating the first signal, measuring intensity of the first signal, and correlating the intensity of the first signal to the first ratio, thereby identifying the first target nucleic acid.

Competitive Probes For Engineering Signal Generation

US Patent:
2019023, Aug 1, 2019
Filed:
Apr 5, 2019
Appl. No.:
16/376411
Inventors:
- Carlsbad CA, US
Aditya RAJAGOPAL - Orange CA, US
Karen L. MENGE - San Marcos CA, US
Gregory GOSCH - San Diego CA, US
International Classification:
C12Q 1/6818
C12Q 1/686
C12Q 1/6816
G01N 33/58
C12Q 1/6804
G01N 21/64
C12Q 1/6888
C12Q 1/6827
Abstract:
A method of identifying a first target nucleic acid comprising, providing a sample comprising the first target nucleic acid, providing a first set of paired oligonucleotides with complementarity to the first target nucleic acid, the first set of paired oligonucleotides comprising a first ratio of (a) first competitive oligonucleotides to (b) first signal oligonucleotides comprising a signal tag, wherein the competitive oligonucleotides compete with the signal oligonucleotides for binding to the first target nucleic acid, amplifying the first target nucleic acid with the polymerase chain reaction, thereby degrading the first signal oligonucleotide and permitting generation of a first signal, generating the first signal, measuring intensity of the first signal, and correlating the intensity of the first signal to the first ratio, thereby identifying the first target nucleic acid.

Competitive Probes For Engineering Signal Generation

US Patent:
2018005, Mar 1, 2018
Filed:
Aug 15, 2017
Appl. No.:
15/677772
Inventors:
- Carlsbad CA, US
Aditya RAJAGOPAL - Orange CA, US
Karen L. MENGE - San Marcos CA, US
Gregory GOSCH - San Diego CA, US
International Classification:
C12Q 1/68
G01N 33/58
G01N 21/64
Abstract:
A method of identifying a first target nucleic acid comprising, providing a sample comprising the first target nucleic acid, providing a first set of paired oligonucleotides with complementarity to the first target nucleic acid, the first set of paired oligonucleotides comprising a first ratio of (a) first competitive oligonucleotides to (b) first signal oligonucleotides comprising a signal tag, wherein the competitive oligonucleotides compete with the signal oligonucleotides for binding to the first target nucleic acid, amplifying the first target nucleic acid with the polymerase chain reaction, thereby degrading the first signal oligonucleotide and permitting generation of a first signal, generating the first signal, measuring intensity of the first signal, and correlating the intensity of the first signal to the first ratio, thereby identifying the first target nucleic acid.

Possible Relatives

Daniel J Menge  Desiree Menge  Donald F Menge  Erich E Menge  Franz R Menge  George H Menge  Adam Menge  Karen L Johnson  Karen J Stamps  Karen B Stanbery 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.